ArticlePediatric nephrology (Berlin, Germany)2006
Risk factors for glucocorticoid-induced obesity in children with steroid-sensitive nephrotic syndrome.
Article in Pediatric nephrology (Berlin, Germany), 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Clinical practice guideline for pediatric idiopathic nephrotic syndrome 2013: general therapy.Clinical and experimental nephrology · 2015Guideline
- Low-dose versus conventional-dose prednisolone for nephrotic syndrome relapses: a randomized controlled non-inferiority trial.Pediatric nephrology (Berlin, Germany) · 2021Trial
- Practice variation in the use of steroid-sparing therapies in childhood steroid-sensitive nephrotic syndrome: results from a prospective cohort study.Pediatric nephrology (Berlin, Germany) · 2025Observational
- Impact of childhood nephrotic syndrome on obesity and growth: a prospective cohort study.Pediatric nephrology (Berlin, Germany) · 2024Article
- Mycophenolate Mofetil Versus Prednisone for Induction Therapy in Steroid-Sensitive Idiopathic Nephrotic Syndrome in Children: An Observational Study.Kidney medicine · 2024Article
- Article
- Long-term obesity prevalence and linear growth in children with idiopathic nephrotic syndrome: is normal growth and weight control possible with steroid-sparing drugs and low-dose steroids for relapses?Pediatric nephrology (Berlin, Germany) · 2022Article
- Treating the idiopathic nephrotic syndrome: are steroids the answer?Pediatric nephrology (Berlin, Germany) · 2019Review
- Subclinical cardiovascular disease and its association with risk factors in children with steroid-resistant nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2014Observational
- Glucocorticoid-related changes in body mass index among children and adolescents with rheumatic diseases.Arthritis care & research · 2013Article
- Factors influencing cardiovascular risk following termination of glucocorticoid therapy for nephrotic syndrome.Clinical and experimental nephrology · 2010Article
- Effect of obesity on response to cardiovascular drugs in pediatric patients with renal disease.Pediatric nephrology (Berlin, Germany) · 2009Article
- Obesity and other clinical endpoints in steroid-sensitive nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2007Article
Corrections and comments
- Commented on by
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
Abstract
The objective of this work was to determine the prevalence of obesity, defined as BMI >95th percentile, in children treated with glucocorticoids for steroid-sensitive nephrotic syndrome (SSNS), and to identify risk factors for the development for glucocorticoid-induced obesity. The experimental design involved a cross-sectional study of 96 individuals (4 to 21 yrs) treated with glucocorticoids for SSNS and 186 healthy reference subjects. Logistic regression was used to generate odds ratios for obesity. Glucocorticoid exposure was classified as recent in the 54 subjects treated with glucocorticoids in the prior six months, and remote in the remaining 42 subjects. Recent exposure was associated with significantly increased odds of obesity [odds ratio (95% CI): 26.14 (7.54, 90.66)] in non-blacks only. Each one-unit increase in maternal BMI was associated with a 35% increase in the odds of obesity in recent SSNS subjects (p=0.003). The effect of maternal BMI on the odds of obesity was significantly greater in recent SSNS subjects than in reference subjects (test for interaction p=0.038). The odds of obesity were also significantly increased [odds ratio 5.22 (1.77, 15.41), p=0.003] in all subjects with remote glucocorticoid exposure (black and non-black). These results indicate that non-black race and increased maternal BMI are risk factors for glucocorticoid-induced obesity in subjects with recent exposure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.